Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

MEDIculous REMeDy Metabolic disease heterogeneity definition, prevention and remission with targeted interventions

Coordinator
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH, Germany
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€4.4m
Total cost
—
Partners
31 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311734

What the project is doing

In the project's own words, from its summary on CORDIS.

Obesity, diabetes and associated complications constitute a rapidly escalating scientific and societal challenge across Europe marked by profound heterogeneity in causes, clinical trajectories and treatment responses. This heterogeneity explains the limited effectiveness of standardized therapies and highlights the need to stratify metabolic disease. To confront this challenge, MEDIculous REMeDy brings together a pan-European, interdisciplinary doctoral network spanning academia, healthcare, industry, public and patient organizations.

The network’s first objective is to train critical and entrepreneurial metabolic health researchers through innovative interdisciplinary, translational and intersectoral training focused on tailored career development, transferable skills and leadership. Gender-responsive research design, open science, public and patient engagement underpin this training culture, equipping DCs with essential skills for academic and non-academic careers.

These early-career researchers will drive – and be shaped by – our scientific objectives: (1) to map metabolic disease heterogeneity across the full disease spectrum from early metabolic dysfunction and obesity to advanced diabetes with complications, and (2) to dissect this heterogeneity from underlying molecular mechanisms to biomarkers, therapeutic targets and treatment responses. To achieve its scientific objectives, the consortium will integrate metabolic medicine and computational systems biology that draw on multi-country European patient cohorts, advanced human in vitro platforms and complementary in vivo disease models.

This novel integrative strategy enables the development of robust patient stratification and personalized therapeutic approaches applicable across European populations, pushing precision medicine forward. By uniting scientific excellence, pioneering training and societal relevance, MEDIculous REMeDy transforms metabolic disease research and precision medicine across Europe.

Topics

Who is involved

OrganisationCityCountryRole
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyCoordinator
Ohmx.bioGentBelgiumAssociatedpartner
The Governors of the University of AlbertaEdmontonCanadaAssociatedpartner
Deutsches Museum Von Meisterwerken Der Naturwissenschaft Und TechnikMunchenGermanyAssociatedpartner
Deutsches Zentrum für Diabetesforschung e.V.OberschleiheimGermanyAssociatedpartner
European Association for the Study of Diabetes (easd) E. V.DusseldorfGermanyAssociatedpartner
Evotec International GmbHHamburgGermanyAssociatedpartner
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyAssociatedpartner
Technische Universitaet MuenchenMuenchenGermanyAssociatedpartner
Universitaet LeipzigLeipzigGermanyParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Fecundis Lab S.l.Sant Cugat Del VallesSpainAssociatedpartner
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Universidad Autonoma De MadridMadridSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
Diabetesseura T1D ryHelsinkiFinlandAssociatedpartner
Helsingin YliopistoHelsinkiFinlandParticipant
Turun YliopistoTurkuFinlandAssociatedpartner
Genos Glycoscience Doo Za Istrazivanje I UslugeOsijekCroatiaParticipant
Sveuciliste U Zagrebu Medicinski FakultetZagrebCroatiaAssociatedpartner
Enamine PL Sp. z o.o.WrocawPolandAssociatedpartner
Sanprobi Spolka Z Ograniczona Odpowiedzialnoscia Spolka KomandytowaSzczecinPolandAssociatedpartner
Warszawski Uniwersytet MedycznyWarszawaPolandParticipant
Universitatea De Vest Din TimisoaraTimisoaraRomaniaParticipant
Kemijski InstitutLjubljanaSloveniaParticipant
Univerza V LjubljaniLjubljanaSloveniaAssociatedpartner
Imperial College of Science Technology and MedicineLondonUnited KingdomParticipant
Ignota Labs LimitedCambridgeUnited KingdomAssociatedpartner
The University of ExeterExeterUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI